Status:
COMPLETED
D-serine Adjuvant Treatment for Parkinson's Disease
Lead Sponsor:
Herzog Hospital
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-75 years
Phase:
PHASE4
Brief Summary
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (\~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced dyskinesias....
Eligibility Criteria
Inclusion
- PD diagnosis
- ≥2 on UPDRS items 32,33
- receive treatment with L-dopa alone or in combination with other antiparkinsonian medications.
Exclusion
- current or previous history of other neurological disorders
- unstable medical conditions
- renal pathology
- pregnant female patients excluded
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00215904
Start Date
August 1 2003
End Date
May 1 2008
Last Update
July 9 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ezrath Nashim - Herzog Memorial Hospital
Jerusalem, Israel, 91351